US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.57

-0.0400-2.48%

Post-market: 1.580.0100+0.64%19:45 EDT

Volume:1.58M

Turnover:2.49M

Market Cap:341.11M

PE:-1.19

High:1.62

Open:1.61

Low:1.54

Close:1.61

Loading ...

Overview Company News Filings

Eyenovia Stock Tumbles on Termination of Phase III Myopia Study

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

Allogene Therapeutics presents data for ALLO-329 in autoimmune disease

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains

JMP Securities Remains a Hold on Allogene Therapeutics (ALLO)

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Stock Track | Allogene Therapeutics Stock Plunges After Disappointing Earnings Report

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

Allogene's Q3 Loss Narrower Than Expected, Sales Nil

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...

Allogene Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary

Allogene Therapeutics Inc : Qtrly Shr Loss $0.32

THOMSON REUTERS

Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate

Allogene Therapeutics: Q3 Earnings Snapshot

Associated Press Finance

Allogene Therapeutics Inc -Continues to Expect Its Cash Runway to Fund Operations Into the Second Half of 2026

THOMSON REUTERS

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALLO/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALLO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALLO\",,,,,undefined,":{"symbol":"ALLO","market":"US","secType":"STK","nameCN":"Allogene Therapeutics Inc.","latestPrice":1.57,"timestamp":1745524800000,"preClose":1.61,"halted":0,"volume":1580308,"hourTrading":{"tag":"盘后","latestPrice":1.58,"preClose":1.57,"latestTime":"19:45 EDT","volume":11749,"amount":18461.52,"timestamp":1745538324249},"delay":0,"floatShares":156266641,"shares":217264738,"eps":-1.32225,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"04-24 16:00:00 EDT","open":1.61,"high":1.62,"low":1.54,"amount":2494033.5519368,"amplitude":0.049689,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.32225,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745568000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1539230400000,"exchange":"NASDAQ","adjPreClose":1.61,"preHourTrading":{"tag":"盘前","latestPrice":1.6001,"preClose":1.61,"latestTime":"09:25 EDT","volume":7063,"amount":11483.1899679,"timestamp":1745501132983},"postHourTrading":{"tag":"盘后","latestPrice":1.58,"preClose":1.57,"latestTime":"19:45 EDT","volume":11749,"amount":18461.52,"timestamp":1745538324249},"volumeRatio":0.788578,"impliedVol":0.6545,"impliedVolPercentile":0.388},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALLO\",,,,,undefined,":{"symbol":"ALLO","floatShares":156266641,"roa":"-27.01%","roe":"-55.13%","lyrEps":-1.32225,"volumeRatio":0.788578,"shares":217264738,"dividePrice":0,"high":1.62,"amplitude":0.049689,"preClose":1.61,"low":1.54,"week52Low":1.23,"pbRate":"0.81","psRate":"15504.80","week52High":3.78,"institutionHeld":0,"latestPrice":1.57,"eps":-1.32225,"divideRate":0,"volume":1580308,"delay":0,"ttmEps":-1.32225,"open":1.61,"prevYearClose":2.13,"prevWeekClose":1.45,"prevMonthClose":1.46,"prevQuarterClose":1.46,"fiveDayClose":1.4,"twentyDayClose":1.57,"sixtyDayClose":1.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALLO\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2484260388","title":"Eyenovia Stock Tumbles on Termination of Phase III Myopia Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484260388","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484260388?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:49","pubTimestamp":1731941340,"startTime":"0","endTime":"0","summary":"Eyenovia, Inc.EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, MicroPine, as a potential treatment for pediatric progressive myopia. MicroPine is EYEN’s proprietary drug-device combination of low-dose atropine administered using the company’s Optejet dispensing platform.The decision was taken after an independent Data Review Committee  determined that the phase III CHAPERONEstudy of MicroPine was unlikely to meet its primary endpoint of less than 0.5 diopter progression in visual acuity over three years.The DRC evaluated safety and efficacy data from 252 patients and found no significant difference in myopia progression between the two treatment groups  and placebo. However, all doses of the candidate and the placebo were well-tolerated in the CHAPERONEstudy, with only mild and infrequent adverse events. The complete study data is yet to be provided to Eyenovia.Based on this DRC feedback, Eyenovia has decided to terminate th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X5f0KWUqd43xLwLZQjf2Jw--~B/aD0zOTI7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/83114bcf5a91754ed7ae3f6080390cd9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X5f0KWUqd43xLwLZQjf2Jw--~B/aD0zOTI7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/83114bcf5a91754ed7ae3f6080390cd9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eyenovia-stock-tumbles-termination-phase-144900203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1571399168.USD","LU0225771236.USD","LU0985481810.HKD","SG9999013999.USD","LU0234572021.USD","BK4139","IE0002270589.USD","BK4505","LU0320765992.SGD","BK4581","BK4134","SG9999001176.SGD","BK4568","LU0234570918.USD","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU2468319806.SGD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","EYEN","BK4583","LU2087621335.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","ALLO","LU1066053197.SGD","PFE","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","BK4566","III","IE00BSNM7G36.USD","BK4578","BK4007","IE00B19Z3581.USD","IE00BKVL7J92.USD","SG9999002232.USD","BK4532","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","GILD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2484234674","title":"ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484234674","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484234674?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:26","pubTimestamp":1731939960,"startTime":"0","endTime":"0","summary":"The ongoing phase I study evaluates the safety, tolerability, pharmacokinetic  and pharmacodynamic effects of nucresiran in 48 healthy adult subjects, who have been randomized in a ratio of 3:1 to receive either a single ascending dose of nucresiran or placebo. The study's primary endpoint is safety and secondary endpoints include the change from baseline in serum TTR over time, as well as characterization of plasma and urine PK of nucresiran.ALNY’s Amyloidosis Drug Shows Sustained 6-Month Efficacy. Per the data from an interim analysis of the phase I ATTR amyloidosis study, it was observed that a single 300 mg or higher dose of nucresiran quickly reduced serum TTR levels with low inter-patient variability, by more than 90% within 15 days, sustained through at least six months. At these dosage strengths, the reduction of mean TTR levels peaked at more than 96% by Day 29. Furthermore, serum TTR levelsremained significantly reduced, with a mean decrease of more than 70% at the one-year m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alny-reports-sustained-6-month-142600613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","BK4139","ALLO","IE00BBT3K403.USD","BK4218","LU1066053197.SGD","SG9999011175.SGD","LU1430594728.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","IE00BKVL7J92.USD","LU1057294990.SGD","IE00BSNM7G36.USD","SG9999013999.USD","LU1839511570.USD","ALNY","BK4533","PFE","BK4583","SG9999001176.SGD","LU0889565916.HKD","LU1585245621.USD","LU0234572021.USD","LU0321505868.SGD","IE00BZ1G4Q59.USD","BK4007","LU1066051498.USD","LU0320765992.SGD","LU1894683264.USD","SG9999003800.SGD","LU0225771236.USD","LU0321505439.SGD","BK4578","IE000M9KFDE8.USD","BK4534","PK","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","BK4566","GILD","IE00B19Z3581.USD","SG9999002232.USD","LU0306807586.USD","SG9999001176.USD","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2484678208","title":"Allogene Therapeutics presents data for ALLO-329 in autoimmune disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484678208","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484678208?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:45","pubTimestamp":1731937526,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics (ALLO) announced preclinical data for ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy being evaluat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allogene-therapeutics-presents-data-for-allo-329-in-autoimmune-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allogene-therapeutics-presents-data-for-allo-329-in-autoimmune-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4230","CAR","ALLO","BK4022","BK4139"],"gpt_icon":0},{"id":"2484562620","title":"Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484562620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484562620?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936600,"startTime":"0","endTime":"0","summary":"ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine ModelsProprietary Dagger Technology Enables ALLO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982777/0/en/Allogene-Therapeutics-Presents-Preclinical-Data-for-ALLO-329-an-Allogeneic-CD19-CD70-Dual-CAR-T-for-the-Treatment-of-Autoimmune-Disease-at-the-American-College-of-Rheumatology-ACR-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","MLR","BK4112","BK4230","CAR","TRAC","ALLO","BK4077","BK4117","ACR","SLE","BK4110","BK4149","AFG","BK4022","BK4139","BK4107"],"gpt_icon":0},{"id":"2483382416","title":"Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2483382416","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483382416?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:24","pubTimestamp":1731597840,"startTime":"0","endTime":"0","summary":"However, Syros reported that the combo drug was well-tolerated by the total enrolled HR-MDS patient population in the SELECT-MDS-1 study. Moreover, the treatment-related adverse events were similar to those observed in earlier company-sponsored studies.Year to date, shares of SYRS have plunged 95.4% compared with theindustry’s 3.8% decline.Based on the disappointing outcome, Syros has decided to stop the HR-MDS study followed by a thorough review of the clinical data to evaluate the next steps. This is a huge setback for the company, leaving SYRS without a pipeline candidate. In the same press release, the company also stated that the failure of the SELECT-MDS-1 study to meet its primary endpoint constitutes an event of default under its secured loan facility with Oxford Finance.SYRS’ Termination of Mid-Stage Leukemia Study in August. The latest stock price drop marks the second pipeline setback for Syros in around three months. In August 2024, Syros stock plummeted after it discontinu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T8SwUImUDIjgxL38j1nI4w--~B/aD00MTQ7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T8SwUImUDIjgxL38j1nI4w--~B/aD00MTQ7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syros-stock-plunges-lead-cancer-152400773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0820561818.USD","LU1093756325.SGD","LU0882574055.USD","LU1989772840.SGD","LU2237443895.HKD","LU2023251221.USD","SG9999011175.SGD","BK4161","IE00BFTCPJ56.SGD","LU0211328371.USD","LU0820561909.HKD","LU1003077747.HKD","LU0203347892.USD","LU2089284900.SGD","ALLO","LU1244550494.USD","LU0965509283.SGD","LU2347655156.SGD","LU1934455863.HKD","LU1267930573.SGD","LU1244550577.SGD","LU0689472784.USD","LU0545039389.USD","IE00B894F039.SGD","LU1496350171.SGD","SG9999015952.SGD","BIIB","LU2237443978.SGD","LU1551013342.USD","ABBV","LU0889565916.HKD","BK4505","LU2133065610.SGD","SYRS","LU0211327993.USD","LU2087621335.USD","BK4588","BK4566","LU1718418525.SGD","LU0203345920.USD","SG9999003800.SGD","LU0738911758.USD","LU1983299246.USD","CR","BK4139","LU2237443382.USD","LU0708994859.HKD","IE00B19Z9P08.USD","LU1430594728.SGD","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2483371358","title":"Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2483371358","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483371358?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:50","pubTimestamp":1731513000,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc.XENE reported a loss of 81 cents per share for the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 82 cents. The company had incurred a loss of 73 cents per share in the year-ago quarter.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.Xenon, in ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q3-loss-narrower-expected-155000607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","BK4505","LU2065169927.USD","LU0109394709.USD","IE00B894F039.SGD","BK4139","IE00B19Z9P08.USD","NBIX","LU2065171311.SGD","IE00B19Z9Z06.USD","LU0320765992.SGD","BIIB","BK4588","LU2065171402.SGD","XENE","ABVC","LU2324357040.USD","BK4533","LU0234570918.USD","ALLO","BK4532","LU2065170008.USD","BK4585","LU0823416689.USD"],"gpt_icon":0},{"id":"2483111038","title":"AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2483111038","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483111038?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:30","pubTimestamp":1731421800,"startTime":"0","endTime":"0","summary":"The studies were designed to show a statistically significant reduction  in the change from baseline in the Positive and Negative Syndrome Scale  total score upon treatment with the candidate compared with the placebo group at week 6. Please note that PANSS isa metric that measures the symptom severity of schizophrenia.The two phase II EMPOWERstudies evaluated emraclidineas a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms. Emraclidineis a potential novel M4-selective PAMin development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need for titration. Year to date, shares of AbbVie have gained 12.6% compared with the industry’s 11.5% growth.ABBV’s Schizophrenia Study Failures Boost BMY Stock. The failure of the EMPOWERstudies is a huge benefit for Bristol Myers as it reduces emerging competition for Cobenfy, which could have resulted in the stock price rise ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-stock-declines-schizophrenia-studies-143000633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","LU0882574055.USD","LU0985320562.USD","LU0061475181.USD","LU2242652126.USD","LU0029864427.USD","LU0949170772.SGD","LU0321505868.SGD","IE00BFTCPJ56.SGD","LU0321505439.SGD","LU0203347892.USD","LU1670710588.SGD","ALLO","LU1585245621.USD","LU0795875086.SGD","IE00BGHQF631.EUR","BK4581","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU0310799852.SGD","LU0689472784.USD","LU2360032135.SGD","BK4533","BIIB","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU0965508806.USD","ABBV","IE00B2B36J28.USD","LU0310800379.SGD","BMY","LU1670710661.SGD","LU0912757837.SGD","LU2242646821.SGD","LU0320765992.SGD","LU0203345920.USD","LU1032466523.USD","LU1093756168.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0985481810.HKD","LU0661504455.SGD","LU0170899867.USD","IE0009355771.USD","BK4550","LU1074936037.SGD","IE00B19Z9P08.USD","LU1430594728.SGD","IE00B19Z9Z06.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2482322504","title":"JMP Securities Remains a Hold on Allogene Therapeutics (ALLO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482322504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482322504?lang=en_us&edition=fundamental","pubTime":"2024-11-11 13:26","pubTimestamp":1731302798,"startTime":"0","endTime":"0","summary":"In a report released today, Reni Benjamin from JMP Securities maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report). The compa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jmp-securities-remains-a-hold-on-allogene-therapeutics-allo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jmp-securities-remains-a-hold-on-allogene-therapeutics-allo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLO","JMP","BK4127","BK4505","BK4139"],"gpt_icon":0},{"id":"2482439537","title":"Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2482439537","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482439537?lang=en_us&edition=fundamental","pubTime":"2024-11-09 01:02","pubTimestamp":1731085320,"startTime":"0","endTime":"0","summary":"Nektar TherapeuticsNKTR incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 23 cents.In the year-ago quarter, the company reported an adjusted  loss of 18 cents.Total revenues remained flat year over year at $24.1 million. The reported figure beat the Zacks Consensus Estimate of $16 million.See the ZacksEarnings Calendar to stay ahead of market-making news.Non-cash royalty revenues were $15.7 million, down around 13% from the year-ago quarter. However, the reported figure beat the Zacks Consensus Estimate of $13.9 million as well as our model estimate of $10.3 million.In November, Nektar signed a definitive agreement with Ampersand Capital Partners to sell its commercial PEGylation Reagent manufacturing business in Huntsville, AL, for $90 million. The sale includes $70 million in cash and $20 million in equity in the new portfolio company. The Huntsville facility will operate independently as an Ampersand portfolio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-q3-loss-narrower-expected-170200070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1064131342.USD","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","LU0354030438.USD","ALLO","LU0096364046.USD","LU0471298694.HKD","NVS","LU0106261372.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU0823416689.USD","LU0203201768.USD","IE0009355771.USD","IE0004445239.USD","BK4581","BK4585","LU0471298777.SGD","LU0820561909.HKD","LU0289739699.SGD","LU0211331839.USD","BK4007","LU0097036916.USD","BK4578","LU0006306889.USD","IE00BJLML261.HKD","LU0238689110.USD","LU0943347566.SGD","BK4505","LLY","LU1061106388.HKD","GB00BDT5M118.USD","LU0466842654.USD","LU1093756168.USD","LU0109391861.USD","LU0320765059.SGD","LU0882574055.USD","LU0708995401.HKD","LU0256863811.USD","LU0820561818.USD","LU1035775433.USD","LU0689472784.USD","NKTR","LU1057294990.SGD","LU0640476718.USD","LU0672654240.SGD","IE0002141913.USD","LU0198837287.USD","LU0354030511.USD","LU0882574139.USD"],"gpt_icon":1},{"id":"1191888401","title":"Stock Track | Allogene Therapeutics Stock Plunges After Disappointing Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1191888401","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191888401?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:48","pubTimestamp":1731084513,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics Inc.  saw its stock price plummet by 6.58% on November 8, 2024, following the release of its earnings report for the quarter ended January 1, 2024.The biotechnology company reported a wider-than-expected adjusted loss of $0.32 per share for the quarter, missing analysts' expectations of a $0.33 loss per share. The company also failed to generate any revenue, while analysts had forecast revenue of $12,930.Allogene Therapeutics reported a quarterly loss of $66.29 million, ref","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALLO"],"gpt_icon":0},{"id":"2482484318","title":"Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2482484318","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482484318?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:38","pubTimestamp":1731080280,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. IMVT reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year-ago quarter's loss of 45 cents per share.Currently, Immunovant does not have any approved product in its portfolio. As a result, it has yet to generate revenues.See the ZacksEarnings Calendar to stay ahead of market-making news.Research and development (R&D) expenses totaled $97.3 million, up 103% from the year-ago quarter’s figure. The massive uptick can be attributed to activities in preparation for potential future clinical studies of IMVT-1402, including contract manufacturing costs for drug substance, higher overall clinical study costs related to batoclimab development programs and increased personnel-related expenses.IMVT may also transition its batoclimab CIDP study to a registrational CIDP program with IMVT-1402.The company believes that the data from the ongoing batoclimab CIDP ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovants-q2-loss-wider-expected-153800243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B894F039.SGD","NVS","IE00B66KJ199.SGD","LU0889565916.HKD","LU0109394709.USD","MG","IE00B4R5TH58.HKD","LU0320765992.SGD","ALLO","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B19Z4B17.USD","BK4578","BK4187","BK4516","BK4123","BK4139","IE0002141913.USD","LU0211331839.USD","BK4550","IMVT","IE00B7SZL793.SGD","BIIB","BK4505","BK4566","BK4585","GD","IE0009355771.USD","IE0031619046.USD","BK4533","BK4007","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4532","BK4588","LU0170899867.USD","LU0234570918.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2482482647","title":"Allogene's Q3 Loss Narrower Than Expected, Sales Nil","url":"https://stock-news.laohu8.com/highlight/detail?id=2482482647","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482482647?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:15","pubTimestamp":1731078900,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO incurred an adjusted loss  of 27 cents per share in third-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents.Inclusive of impairment charges, the company posted a loss of 32 cents per share in the quarter. In the year-ago period, the company reported a loss of 37 cents. There was no impairment charge in the year-ago period.Allogene did not generate revenues during the reported quarter. The Zacks Consensus Estimate for third-quarter sales was pegged at $0.04 million. In the year-ago period, management recorded revenues of $0.02 million.Year to date, shares of Allogene have lost 0.6% compared with the industry’s 2.4% decline.Research & development (R&D) expenses totaled $44.7 million, down 3% from the year-ago quarter’s level.During the first quarter, management started a new cohort in the phase I ALPHA2 study evaluating cema-cel in patients with chronic lymphocytic leukemia  based on investigator enthusiasm. It in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogenes-q3-loss-narrower-expected-151500919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALLO"],"gpt_icon":0},{"id":"2481910692","title":"Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481910692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481910692?lang=en_us&edition=fundamental","pubTime":"2024-11-08 22:10","pubTimestamp":1731075019,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cartesian Therapeutics (RNAC – Research Report), Allogene Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-allogene-therapeutics-allo-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-allogene-therapeutics-allo-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","RNAC","BK4505","BK4534","MRNA","BK4532","BK4501","HCSG","ALLO","BK4551","BK4585","BK4588","BK4548","BK4533","BK4139","BK4568"],"gpt_icon":0},{"id":"2481176530","title":"Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2481176530","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481176530?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:07","pubTimestamp":1731064044,"startTime":"0","endTime":"0","summary":"Cash Balance: $403.4 million as of the end of Q3 2024.Cash Runway: Extends into the second half of 2026.Research and Development Expenses: $44.7 million in Q3 2024, including $5.6 million in noncash stock-based compensation.General and Administrative Expenses: $16.3 million in Q3 2024, including $7.8 million in noncash stock-based compensation.Net Loss: $66.3 million or 32 per share in Q3 2024.Noncash Stock-Based Compensation Expense: $13.4 million in Q3 2024.Noncash Impairment of Long-Lived Asset Expense: $10.7 million in Q3 2024.Expected Cash Burn for 2024: Approximately $200 million.Expected Full Year 2024 GAAP Operating Expenses: Approximately $300 million, including $60 million in noncash stock-based compensation.GuruFocus has detected 3 Warning Signs with ALLO.Allogene Therapeutics Inc  is advancing its pivotal Phase 2 ALPHA3 trial for large B cell lymphoma, which could set a new standard for first-line treatment.Allogene Therapeutics Inc  is innovating in autoimmune diseases wit","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VsyEIJH467qZkxWChf_XxA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0f6f606402de314a4119055e40951a31","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VsyEIJH467qZkxWChf_XxA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0f6f606402de314a4119055e40951a31"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-q3-110724066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALLO"],"gpt_icon":0},{"id":"2481118401","title":"Allogene Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481118401","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481118401?lang=en_us&edition=fundamental","pubTime":"2024-11-08 13:16","pubTimestamp":1731043004,"startTime":"0","endTime":"0","summary":"* Allogene Therapeutics Inc    reported a quarterly adjusted loss of 32 cents per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -37 ce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ALLO"],"gpt_icon":0},{"id":"2481168628","title":"Allogene Therapeutics Inc : Qtrly Shr Loss $0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2481168628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481168628?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:06","pubTimestamp":1731017215,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME21C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","ALLO"],"gpt_icon":0},{"id":"2481345150","title":"Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481345150","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481345150?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:37","pubTimestamp":1731015458,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41825883/allogene-therapeutics-q3-2024-gaap-eps-0-32-beats-0-33-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ALLO"],"gpt_icon":0},{"id":"2481933311","title":"Allogene Therapeutics: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481933311","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481933311?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:11","pubTimestamp":1731013901,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif.  — SOUTH SAN FRANCISCO, Calif.  — Allogene Therapeutics Inc.  on Thursday reported a loss of $66.3 million in its third quarter.On a per-share basis, the South San Francisco, California-based company said it had a loss of 32 cents. Losses, adjusted for asset impairment costs, were 27 cents per share.The results exceeded Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.In the final minutes of trading on Thursday, the company's shares hit $3.20. A year ago, they were trading at $3.28.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-q3-earnings-snapshot-211141817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","ALLO"],"gpt_icon":0},{"id":"2481157388","title":"Allogene Therapeutics Inc -Continues to Expect Its Cash Runway to Fund Operations Into the Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2481157388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481157388?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:02","pubTimestamp":1731013320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA6WWBCB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLO","BK4505"],"gpt_icon":0},{"id":"2481332193","title":"CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2481332193","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481332193?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:29","pubTimestamp":1730993340,"startTime":"0","endTime":"0","summary":"Total revenues, the majority of which comprised product revenues, amounted to $128.7 million in the reported quarter, representing growth of 25.3% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $123 million.Catalyst’s top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome  and epilepsy drug, Fycompa  CIII. Revenues generated from the sale of the newly launched muscle disease drug, Agamree , also contributed to the top line.The stock gained 7% in the after-market hours on Nov. 6 as the investors were impressed by the better-than-expected third-quarter results.See the ZacksEarnings Calendar to stay ahead of market-making news.Firdapse generated sales worth $79.3 million in the reported quarter, up 19.7% year over year. The reported figure beat the Zacks Consensus Estimate of $77.6 million and our estimate of $77.2 million, driven by the organic sales growth of Fird","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cprx-q3-earnings-revenues-beat-152900062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CPRX","ALLO","NVS"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":95,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALLO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"ALLO","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2024-11-07","symbol":"ALLO","fiscalQuarterEnding":"2024/09","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-08-07","symbol":"ALLO","fiscalQuarterEnding":"2024/06","expectedEps":-0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2024-05-13","symbol":"ALLO","fiscalQuarterEnding":"2024/03","expectedEps":-0.38,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2024-03-14","symbol":"ALLO","fiscalQuarterEnding":"2023/12","expectedEps":-0.47,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710388800000,"reportTimeType":"post","actualEps":-0.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALLO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALLO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5333,"hold":0.1333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5333,"analysts":15,"updateTime":1742011200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALLO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALLO","date":"2025-04-23","current":-1.341088,"percent":0.958604,"low":-32.642437,"twenty":-16.455771,"median":-4.465773,"eighty":-1.82327,"high":-1.035677,"avg":-8.285436,"sd":8.084139,"marketCap":345450933},"quantilePoints":[{"date":"2020-05-01","current":-19.313172,"twenty":-128717.983625,"median":-20.985914,"eighty":-14.920302,"marketCap":3565095674},{"date":"2020-05-08","current":-18.972964,"twenty":-128670.395667,"median":-20.938532,"eighty":-14.923683,"marketCap":3936662257},{"date":"2020-05-15","current":-27.127532,"twenty":-128214.835667,"median":-20.927873,"eighty":-14.959059,"marketCap":5628637440},{"date":"2020-05-22","current":-32.642437,"twenty":-127115.307333,"median":-20.988186,"eighty":-15.034865,"marketCap":6772913989},{"date":"2020-05-29","current":-29.090669,"twenty":-125818.1121,"median":-21.018149,"eighty":-15.038908,"marketCap":6035964799},{"date":"2020-06-05","current":-28.154608,"twenty":-125362.460425,"median":-21.101225,"eighty":-15.042238,"marketCap":5841743348},{"date":"2020-06-12","current":-26.741264,"twenty":-125167.645342,"median":-21.34254,"eighty":-15.052628,"marketCap":5548491395},{"date":"2020-06-19","current":-26.351604,"twenty":-123317.452191,"median":-21.370232,"eighty":-15.067209,"marketCap":5467641557},{"date":"2020-06-26","current":-28.372554,"twenty":-122766.755092,"median":-21.425301,"eighty":-15.085062,"marketCap":5886964444},{"date":"2020-07-02","current":-29.693436,"twenty":-122411.666725,"median":-21.484956,"eighty":-15.099106,"marketCap":6161031690},{"date":"2020-07-10","current":-28.628112,"twenty":-122130.57855,"median":-21.512647,"eighty":-15.112891,"marketCap":5939989714},{"date":"2020-07-17","current":-28.41417,"twenty":-120852.809358,"median":-21.632371,"eighty":-15.149784,"marketCap":5895599320},{"date":"2020-07-24","current":-25.786695,"twenty":-118796.77005,"median":-21.690696,"eighty":-15.211389,"marketCap":5350429782},{"date":"2020-07-31","current":-24.516415,"twenty":-117386.342967,"median":-21.749941,"eighty":-15.262228,"marketCap":5086861813},{"date":"2020-08-07","current":-23.068229,"twenty":-116963.771775,"median":-21.815069,"eighty":-15.302048,"marketCap":5241539822},{"date":"2020-08-14","current":-22.639109,"twenty":-115764.848892,"median":-21.850929,"eighty":-15.323938,"marketCap":5144035759},{"date":"2020-08-21","current":-22.326465,"twenty":-113858.364958,"median":-21.88451,"eighty":-15.339533,"marketCap":5072997085},{"date":"2020-08-28","current":-21.449836,"twenty":-113052.531558,"median":-21.850929,"eighty":-15.350911,"marketCap":4873810214},{"date":"2020-09-04","current":-20.248302,"twenty":-113013.222625,"median":-21.815069,"eighty":-15.356579,"marketCap":4600798839},{"date":"2020-09-11","current":-19.849834,"twenty":-112698.751042,"median":-21.773611,"eighty":-15.368663,"marketCap":4510259352},{"date":"2020-09-18","current":-23.295049,"twenty":-111676.7184,"median":-21.798486,"eighty":-15.39431,"marketCap":5293077684},{"date":"2020-09-25","current":-22.694282,"twenty":-110733.303667,"median":-21.781903,"eighty":-15.424201,"marketCap":5156571996},{"date":"2020-10-02","current":-22.42455,"twenty":-66346.905025,"median":-21.833475,"eighty":-15.446635,"marketCap":5095283728},{"date":"2020-10-09","current":-25.465166,"twenty":-32.123278,"median":-21.864819,"eighty":-15.456704,"marketCap":5786169657},{"date":"2020-10-16","current":-24.049073,"twenty":-31.053945,"median":-21.899539,"eighty":-15.474746,"marketCap":5464406251},{"date":"2020-10-23","current":-22.252902,"twenty":-30.499998,"median":-21.914568,"eighty":-15.494275,"marketCap":5056282103},{"date":"2020-10-30","current":-20.793896,"twenty":-30.117541,"median":-21.899539,"eighty":-15.519547,"marketCap":4724768290},{"date":"2020-11-06","current":-16.069607,"twenty":-29.763062,"median":-21.864819,"eighty":-15.5887,"marketCap":3899788225},{"date":"2020-11-13","current":-18.537852,"twenty":-29.652871,"median":-21.833475,"eighty":-15.667503,"marketCap":4498784474},{"date":"2020-11-20","current":-18.052296,"twenty":-29.579943,"median":-21.805392,"eighty":-15.676049,"marketCap":4380949146},{"date":"2020-11-27","current":-18.219928,"twenty":-29.522101,"median":-21.773611,"eighty":-15.706189,"marketCap":4421630391},{"date":"2020-12-04","current":-19.451161,"twenty":-29.361862,"median":-21.722315,"eighty":-15.79419,"marketCap":4720427114},{"date":"2020-12-11","current":-15.84995,"twenty":-29.3261,"median":-21.682404,"eighty":-15.838198,"marketCap":3846481767},{"date":"2020-12-18","current":-15.688098,"twenty":-29.203647,"median":-21.66746,"eighty":-15.734976,"marketCap":3807203325},{"date":"2020-12-24","current":-15.797926,"twenty":-29.199397,"median":-21.632371,"eighty":-15.783758,"marketCap":3833856554},{"date":"2020-12-31","current":-14.589816,"twenty":-29.129678,"median":-21.578578,"eighty":-15.683214,"marketCap":3540671036},{"date":"2021-01-08","current":-16.11007,"twenty":-29.094985,"median":-21.512647,"eighty":-15.665105,"marketCap":3909607836},{"date":"2021-01-15","current":-18.722826,"twenty":-29.085837,"median":-21.484956,"eighty":-15.668424,"marketCap":4543674123},{"date":"2021-01-22","current":-17.780615,"twenty":-29.081387,"median":-21.441682,"eighty":-15.679632,"marketCap":4315017475},{"date":"2021-01-29","current":-20.058106,"twenty":-29.079226,"median":-21.417075,"eighty":-15.687578,"marketCap":4867721274},{"date":"2021-02-05","current":-20.358689,"twenty":-29.059413,"median":-21.366276,"eighty":-15.695035,"marketCap":4940666953},{"date":"2021-02-12","current":-20.075448,"twenty":-28.895623,"median":-21.330672,"eighty":-15.713532,"marketCap":4871929678},{"date":"2021-02-19","current":-20.069667,"twenty":-28.779198,"median":-21.3211,"eighty":-15.747172,"marketCap":4870526877},{"date":"2021-02-26","current":-19.510296,"twenty":-28.705134,"median":-21.268993,"eighty":-15.789425,"marketCap":4881885762},{"date":"2021-03-05","current":-19.111209,"twenty":-28.62932,"median":-21.180345,"eighty":-15.813122,"marketCap":4782025812},{"date":"2021-03-12","current":-21.629392,"twenty":-28.549665,"median":-21.223136,"eighty":-15.840479,"marketCap":5412128036},{"date":"2021-03-19","current":-20.803113,"twenty":-28.424864,"median":-21.180345,"eighty":-15.848374,"marketCap":5205375744},{"date":"2021-03-26","current":-18.987548,"twenty":-28.40809,"median":-21.126559,"eighty":-15.84995,"marketCap":4751083292},{"date":"2021-04-01","current":-19.633957,"twenty":-28.393688,"median":-21.081445,"eighty":-15.853418,"marketCap":4912828282},{"date":"2021-04-09","current":-18.447938,"twenty":-28.354062,"median":-21.006281,"eighty":-15.878853,"marketCap":4616061386},{"date":"2021-04-16","current":-18.273688,"twenty":-28.264241,"median":-20.976017,"eighty":-15.933588,"marketCap":4572460563},{"date":"2021-04-23","current":-19.462576,"twenty":-28.191593,"median":-20.927873,"eighty":-15.982492,"marketCap":4869945125},{"date":"2021-04-30","current":-17.483522,"twenty":-28.153287,"median":-20.900528,"eighty":-16.044634,"marketCap":4374744429},{"date":"2021-05-07","current":-18.574304,"twenty":-28.140827,"median":-20.824306,"eighty":-16.056451,"marketCap":4248983398},{"date":"2021-05-14","current":-17.015102,"twenty":-28.110712,"median":-20.785365,"eighty":-16.066082,"marketCap":3892306577},{"date":"2021-05-21","current":-16.09938,"twenty":-28.045215,"median":-20.757114,"eighty":-16.075562,"marketCap":3682829714},{"date":"2021-05-28","current":-15.901386,"twenty":-27.798929,"median":-20.702003,"eighty":-15.982492,"marketCap":3637537419},{"date":"2021-06-04","current":-14.731984,"twenty":-27.771552,"median":-20.677935,"eighty":-15.867292,"marketCap":3370029804},{"date":"2021-06-11","current":-16.148878,"twenty":-27.752287,"median":-20.584126,"eighty":-15.84995,"marketCap":3694152788},{"date":"2021-06-18","current":-15.146534,"twenty":-27.745135,"median":-20.567167,"eighty":-15.783758,"marketCap":3464860546},{"date":"2021-06-25","current":-14.960915,"twenty":-27.705487,"median":-20.54455,"eighty":-15.697205,"marketCap":3422399019},{"date":"2021-07-02","current":-16.26025,"twenty":-27.672486,"median":-20.524004,"eighty":-15.697205,"marketCap":3719629703},{"date":"2021-07-09","current":-14.911416,"twenty":-27.651352,"median":-20.43363,"eighty":-15.668424,"marketCap":3411075946},{"date":"2021-07-16","current":-14.001882,"twenty":-27.614367,"median":-20.349588,"eighty":-15.61339,"marketCap":3203014467},{"date":"2021-07-23","current":-13.643018,"twenty":-27.477084,"median":-20.242529,"eighty":-15.573595,"marketCap":3120922183},{"date":"2021-07-30","current":-13.581145,"twenty":-27.372009,"median":-20.19926,"eighty":-15.486486,"marketCap":3106768340},{"date":"2021-08-06","current":-13.937332,"twenty":-27.187994,"median":-20.183031,"eighty":-15.440342,"marketCap":3327091981},{"date":"2021-08-13","current":-12.769931,"twenty":-27.13327,"median":-20.135965,"eighty":-15.396829,"marketCap":3048412481},{"date":"2021-08-20","current":-13.967112,"twenty":-27.128016,"median":-20.084647,"eighty":-15.357651,"marketCap":3334201152},{"date":"2021-08-27","current":-14.532944,"twenty":-27.087978,"median":-20.058106,"eighty":-15.319398,"marketCap":3469275399},{"date":"2021-09-03","current":-15.17025,"twenty":-27.066547,"median":-19.991439,"eighty":-15.277942,"marketCap":3621411656},{"date":"2021-09-10","current":-14.735453,"twenty":-26.951342,"median":-19.940072,"eighty":-15.211389,"marketCap":3517617761},{"date":"2021-09-17","current":-15.116645,"twenty":-26.795343,"median":-19.884693,"eighty":-15.124129,"marketCap":3608615148},{"date":"2021-09-24","current":-15.283416,"twenty":-26.678135,"median":-19.849922,"eighty":-15.11715,"marketCap":3648426505},{"date":"2021-10-01","current":-14.604418,"twenty":-26.569222,"median":-19.821108,"eighty":-15.112387,"marketCap":3486337409},{"date":"2021-10-08","current":-7.820392,"twenty":-26.52467,"median":-19.746249,"eighty":-15.06736,"marketCap":1866868278},{"date":"2021-10-15","current":-9.815694,"twenty":-26.488509,"median":-19.739643,"eighty":-15.039637,"marketCap":2343182728},{"date":"2021-10-22","current":-9.422589,"twenty":-26.410782,"median":-19.66854,"eighty":-14.968339,"marketCap":2249341672},{"date":"2021-10-29","current":-10.268359,"twenty":-26.360977,"median":-19.633957,"eighty":-14.938394,"marketCap":2451242126},{"date":"2021-11-05","current":-11.448707,"twenty":-26.35097,"median":-19.577031,"eighty":-14.909523,"marketCap":2870270991},{"date":"2021-11-12","current":-10.948466,"twenty":-26.268966,"median":-19.520526,"eighty":-14.896677,"marketCap":2744856965},{"date":"2021-11-19","current":-10.69266,"twenty":-25.997664,"median":-19.458331,"eighty":-14.830197,"marketCap":2680724793},{"date":"2021-11-26","current":-10.220842,"twenty":-25.82651,"median":-19.416087,"eighty":-14.809383,"marketCap":2562436565},{"date":"2021-12-03","current":-10.016198,"twenty":-25.773439,"median":-19.283528,"eighty":-14.742014,"marketCap":2511130827},{"date":"2021-12-10","current":-10.249265,"twenty":-25.711764,"median":-19.163016,"eighty":-14.695169,"marketCap":2569562362},{"date":"2021-12-17","current":-8.987292,"twenty":-25.583781,"median":-19.115579,"eighty":-14.620796,"marketCap":2253176979},{"date":"2021-12-23","current":-8.902023,"twenty":-25.481704,"median":-19.099967,"eighty":-14.591026,"marketCap":2231799589},{"date":"2021-12-31","current":-8.481366,"twenty":-25.460584,"median":-19.052311,"eighty":-14.49675,"marketCap":2126337794},{"date":"2022-01-07","current":-7.65142,"twenty":-25.434926,"median":-18.972964,"eighty":-14.45075,"marketCap":1918264525},{"date":"2022-01-14","current":-7.549098,"twenty":-25.370845,"median":-18.912042,"eighty":-14.374511,"marketCap":1892611656},{"date":"2022-01-21","current":-6.457662,"twenty":-25.231783,"median":-18.839368,"eighty":-14.322288,"marketCap":1618981055},{"date":"2022-01-28","current":-6.037004,"twenty":-25.124812,"median":-18.790783,"eighty":-14.276831,"marketCap":1513519261},{"date":"2022-02-04","current":-6.264387,"twenty":-25.073649,"median":-18.741054,"eighty":-14.246482,"marketCap":1570525636},{"date":"2022-02-11","current":-5.76983,"twenty":-24.932692,"median":-18.689285,"eighty":-14.211106,"marketCap":1446536770},{"date":"2022-02-18","current":-5.286642,"twenty":-24.919572,"median":-18.675482,"eighty":-14.155515,"marketCap":1325398223},{"date":"2022-02-25","current":-5.237841,"twenty":-24.910169,"median":-18.641491,"eighty":-14.089501,"marketCap":1346151378},{"date":"2022-03-04","current":-4.465773,"twenty":-24.856433,"median":-18.614852,"eighty":-13.975129,"marketCap":1147726096},{"date":"2022-03-11","current":-4.537981,"twenty":-24.80629,"median":-18.575761,"eighty":-13.919313,"marketCap":1166283856},{"date":"2022-03-18","current":-5.421138,"twenty":-24.791816,"median":-18.537852,"eighty":-13.824271,"marketCap":1393259539},{"date":"2022-03-25","current":-5.360039,"twenty":-24.745062,"median":-18.517177,"eighty":-13.759752,"marketCap":1377556819},{"date":"2022-04-01","current":-5.24895,"twenty":-24.663369,"median":-18.481663,"eighty":-13.698958,"marketCap":1349006418},{"date":"2022-04-08","current":-4.910129,"twenty":-24.556916,"median":-18.469454,"eighty":-13.641781,"marketCap":1261927697},{"date":"2022-04-14","current":-4.608672,"twenty":-24.523728,"median":-18.439507,"eighty":-13.603773,"marketCap":1184451691},{"date":"2022-04-22","current":-4.35729,"twenty":-24.477635,"median":-18.313035,"eighty":-13.564932,"marketCap":1119845235},{"date":"2022-04-29","current":-4.665479,"twenty":-24.441832,"median":-18.271722,"eighty":-13.51369,"marketCap":1199051399},{"date":"2022-05-06","current":-4.338635,"twenty":-24.350625,"median":-18.24883,"eighty":-13.47653,"marketCap":1318250882},{"date":"2022-05-13","current":-3.41703,"twenty":-24.272198,"median":-18.214147,"eighty":-13.43938,"marketCap":1038230270},{"date":"2022-05-20","current":-3.535184,"twenty":-24.194972,"median":-18.163547,"eighty":-13.367297,"marketCap":1074130348},{"date":"2022-05-27","current":-3.780946,"twenty":-24.101793,"median":-18.077113,"eighty":-13.243821,"marketCap":1148802512},{"date":"2022-06-03","current":-3.932183,"twenty":-24.060108,"median":-18.06159,"eighty":-13.190251,"marketCap":1194754612},{"date":"2022-06-10","current":-4.603301,"twenty":-24.027743,"median":-17.98293,"eighty":-13.117204,"marketCap":1398667058},{"date":"2022-06-17","current":-5.179895,"twenty":-23.989114,"median":-17.951138,"eighty":-12.938707,"marketCap":1573859441},{"date":"2022-06-24","current":-5.803751,"twenty":-23.979164,"median":-17.921762,"eighty":-12.772357,"marketCap":1763411855},{"date":"2022-07-01","current":-5.439835,"twenty":-23.96372,"median":-17.857317,"eighty":-12.530495,"marketCap":1652839614},{"date":"2022-07-08","current":-5.685597,"twenty":-23.901946,"median":-17.780615,"eighty":-12.328703,"marketCap":1727511777},{"date":"2022-07-15","current":-6.054239,"twenty":-23.879665,"median":-17.691917,"eighty":-11.170164,"marketCap":1839520022},{"date":"2022-07-22","current":-6.314179,"twenty":-23.828383,"median":-17.626932,"eighty":-10.948466,"marketCap":1918500195},{"date":"2022-07-29","current":-6.134584,"twenty":-23.705543,"median":-17.59185,"eighty":-10.800667,"marketCap":1863932075},{"date":"2022-08-05","current":-7.306677,"twenty":-23.697251,"median":-17.538967,"eighty":-10.69266,"marketCap":2220060854},{"date":"2022-08-12","current":-8.062204,"twenty":-23.570911,"median":-17.452841,"eighty":-10.510754,"marketCap":2480667731},{"date":"2022-08-19","current":-6.921811,"twenty":-23.514837,"median":-17.370093,"eighty":-10.266318,"marketCap":2129779078},{"date":"2022-08-26","current":-6.59465,"twenty":-23.443168,"median":-17.343792,"eighty":-10.220842,"marketCap":2029114300},{"date":"2022-09-02","current":-6.636713,"twenty":-23.37196,"median":-17.295567,"eighty":-9.815694,"marketCap":2042056915},{"date":"2022-09-09","current":-7.043329,"twenty":-23.333983,"median":-17.225694,"eighty":-9.494063,"marketCap":2167168852},{"date":"2022-09-16","current":-6.389005,"twenty":-23.304303,"median":-17.168273,"eighty":-9.413059,"marketCap":1965839297},{"date":"2022-09-23","current":-4.963514,"twenty":-23.295891,"median":-17.123016,"eighty":-8.970238,"marketCap":1527228481},{"date":"2022-09-30","current":-5.047641,"twenty":-23.22545,"median":-17.01924,"eighty":-8.791743,"marketCap":1553113710},{"date":"2022-10-07","current":-4.841996,"twenty":-23.18815,"median":-16.933399,"eighty":-8.734897,"marketCap":1489838707},{"date":"2022-10-14","current":-4.757869,"twenty":-23.163275,"median":-16.832624,"eighty":-8.377907,"marketCap":1463953478},{"date":"2022-10-21","current":-4.701784,"twenty":-23.131767,"median":-16.626752,"eighty":-8.053946,"marketCap":1446696659},{"date":"2022-10-28","current":-5.03362,"twenty":-23.123748,"median":-16.609019,"eighty":-7.819568,"marketCap":1548799505},{"date":"2022-11-04","current":-4.308044,"twenty":-23.118497,"median":-16.462729,"eighty":-7.719634,"marketCap":1346922838},{"date":"2022-11-11","current":-4.621692,"twenty":-23.078037,"median":-16.372736,"eighty":-7.512226,"marketCap":1444985743},{"date":"2022-11-18","current":-4.723166,"twenty":-23.040787,"median":-16.295044,"eighty":-7.268603,"marketCap":1476711976},{"date":"2022-11-25","current":-4.967627,"twenty":-23.028761,"median":-16.231769,"eighty":-7.107827,"marketCap":1553143358},{"date":"2022-12-02","current":-4.363393,"twenty":-22.975759,"median":-16.162506,"eighty":-6.958297,"marketCap":1364228056},{"date":"2022-12-09","current":-4.040521,"twenty":-22.92282,"median":-16.136504,"eighty":-6.795851,"marketCap":1263280949},{"date":"2022-12-16","current":-3.187214,"twenty":-22.884679,"median":-16.118741,"eighty":-6.737666,"marketCap":996492164},{"date":"2022-12-23","current":-2.74903,"twenty":-22.855762,"median":-16.09938,"eighty":-6.648267,"marketCap":859492517},{"date":"2022-12-30","current":-2.901242,"twenty":-22.845812,"median":-16.065201,"eighty":-6.624678,"marketCap":907081868},{"date":"2023-01-06","current":-2.808992,"twenty":-22.842858,"median":-16.042226,"eighty":-6.551135,"marketCap":878239837},{"date":"2023-01-13","current":-3.256401,"twenty":-22.839916,"median":-15.931803,"eighty":-6.459821,"marketCap":1018123687},{"date":"2023-01-20","current":-3.021166,"twenty":-22.833946,"median":-15.884339,"eighty":-6.44509,"marketCap":944576508},{"date":"2023-01-27","current":-3.653074,"twenty":-22.804627,"median":-15.84995,"eighty":-6.403977,"marketCap":1142144419},{"date":"2023-02-03","current":-3.588499,"twenty":-22.792366,"median":-15.822247,"eighty":-6.365636,"marketCap":1121954998},{"date":"2023-02-10","current":-3.168765,"twenty":-22.752014,"median":-15.783758,"eighty":-6.281441,"marketCap":990723757},{"date":"2023-02-17","current":-3.320976,"twenty":-22.724933,"median":-15.698432,"eighty":-6.150644,"marketCap":1038313108},{"date":"2023-02-24","current":-2.855117,"twenty":-22.720065,"median":-15.692652,"eighty":-6.050792,"marketCap":892660853},{"date":"2023-03-03","current":-2.602093,"twenty":-22.718848,"median":-15.668884,"eighty":-5.957523,"marketCap":865539324},{"date":"2023-03-10","current":-2.476115,"twenty":-22.699195,"median":-15.650358,"eighty":-5.791024,"marketCap":823635083},{"date":"2023-03-17","current":-2.38489,"twenty":-22.694036,"median":-15.59202,"eighty":-5.754599,"marketCap":793290632},{"date":"2023-03-24","current":-2.180719,"twenty":-22.650082,"median":-15.578958,"eighty":-5.643062,"marketCap":725376862},{"date":"2023-03-31","current":-2.145966,"twenty":-22.606719,"median":-15.536778,"eighty":-5.533933,"marketCap":713817072},{"date":"2023-04-06","current":-2.145966,"twenty":-22.596133,"median":-15.486836,"eighty":-5.526161,"marketCap":713817072},{"date":"2023-04-14","current":-2.193751,"twenty":-22.59183,"median":-15.476469,"eighty":-5.47859,"marketCap":729711784},{"date":"2023-04-21","current":-2.167687,"twenty":-22.582762,"median":-15.444878,"eighty":-5.423849,"marketCap":721041941},{"date":"2023-04-28","current":-2.331585,"twenty":-22.567942,"median":-15.411502,"eighty":-5.378822,"marketCap":775559814},{"date":"2023-05-05","current":-2.67629,"twenty":-22.556495,"median":-15.387839,"eighty":-5.296718,"marketCap":940678449},{"date":"2023-05-12","current":-2.564259,"twenty":-22.5382,"median":-15.360906,"eighty":-5.264421,"marketCap":901301211},{"date":"2023-05-19","current":-2.522766,"twenty":-22.523168,"median":-15.347235,"eighty":-5.220067,"marketCap":886717049},{"date":"2023-05-26","current":-2.26966,"twenty":-22.494685,"median":-15.329523,"eighty":-5.146724,"marketCap":797753661},{"date":"2023-06-02","current":-2.207421,"twenty":-22.461519,"median":-15.318827,"eighty":-5.12616,"marketCap":775877418},{"date":"2023-06-09","current":-2.406586,"twenty":-22.436936,"median":-15.307241,"eighty":-5.087067,"marketCap":845881396},{"date":"2023-06-16","current":-2.062196,"twenty":-22.431982,"median":-15.280863,"eighty":-5.062594,"marketCap":724832851},{"date":"2023-06-23","current":-1.950165,"twenty":-22.42371,"median":-15.264093,"eighty":-5.040163,"marketCap":685455614},{"date":"2023-06-30","current":-1.900373,"twenty":-22.420352,"median":-15.20471,"eighty":-4.999,"marketCap":667954619},{"date":"2023-07-07","current":-2.082942,"twenty":-22.399189,"median":-15.158392,"eighty":-4.959528,"marketCap":732124932},{"date":"2023-07-14","current":-2.163853,"twenty":-22.385151,"median":-15.117486,"eighty":-4.907907,"marketCap":760564048},{"date":"2023-07-21","current":-2.190823,"twenty":-22.379709,"median":-15.097383,"eighty":-4.870137,"marketCap":770043753},{"date":"2023-07-28","current":-1.962613,"twenty":-22.365629,"median":-15.070241,"eighty":-4.834519,"marketCap":689830862},{"date":"2023-08-04","current":-2.429176,"twenty":-22.333634,"median":-15.048949,"eighty":-4.780355,"marketCap":861599516},{"date":"2023-08-11","current":-1.989656,"twenty":-22.302039,"median":-15.039215,"eighty":-4.750531,"marketCap":705706996},{"date":"2023-08-18","current":-1.890409,"twenty":-22.281125,"median":-14.976471,"eighty":-4.726099,"marketCap":670505460},{"date":"2023-08-25","current":-1.800615,"twenty":-22.26271,"median":-14.959059,"eighty":-4.690269,"marketCap":638656450},{"date":"2023-09-01","current":-1.838423,"twenty":-22.254128,"median":-14.935942,"eighty":-4.655464,"marketCap":652066559},{"date":"2023-09-08","current":-1.890409,"twenty":-22.226501,"median":-14.915859,"eighty":-4.613716,"marketCap":670505460},{"date":"2023-09-15","current":-1.866779,"twenty":-22.199407,"median":-14.907739,"eighty":-4.562564,"marketCap":662124141},{"date":"2023-09-22","current":-1.758081,"twenty":-22.155099,"median":-14.902096,"eighty":-4.535759,"marketCap":623570077},{"date":"2023-09-29","current":-1.611574,"twenty":-22.125027,"median":-14.890312,"eighty":-4.47888,"marketCap":571605904},{"date":"2023-10-06","current":-1.488697,"twenty":-22.083887,"median":-14.828304,"eighty":-4.453624,"marketCap":528023049},{"date":"2023-10-13","current":-1.398903,"twenty":-22.021504,"median":-14.806926,"eighty":-4.392913,"marketCap":496174040},{"date":"2023-10-20","current":-1.408355,"twenty":-21.920407,"median":-14.732656,"eighty":-4.341249,"marketCap":499526567},{"date":"2023-10-27","current":-1.24767,"twenty":-21.858588,"median":-14.678091,"eighty":-4.324649,"marketCap":442533603},{"date":"2023-11-03","current":-1.500595,"twenty":-21.791299,"median":-14.597163,"eighty":-4.250351,"marketCap":499480406},{"date":"2023-11-10","current":-1.271472,"twenty":-21.701761,"median":-14.505855,"eighty":-4.13646,"marketCap":423215804},{"date":"2023-11-17","current":-1.420611,"twenty":-21.666847,"median":-14.444042,"eighty":-3.884921,"marketCap":472857420},{"date":"2023-11-24","current":-1.435778,"twenty":-21.606973,"median":-14.367423,"eighty":-3.736519,"marketCap":477905720},{"date":"2023-12-01","current":-1.188055,"twenty":-21.531996,"median":-14.285577,"eighty":-3.670601,"marketCap":395450155},{"date":"2023-12-08","current":-1.274,"twenty":-21.460314,"median":-14.255927,"eighty":-3.607628,"marketCap":424057188},{"date":"2023-12-15","current":-1.370055,"twenty":-21.374979,"median":-14.211106,"eighty":-3.560824,"marketCap":456029754},{"date":"2023-12-22","current":-1.395333,"twenty":-21.322326,"median":-14.13984,"eighty":-3.533294,"marketCap":464443587},{"date":"2023-12-29","current":-1.653166,"twenty":-21.268379,"median":-14.008069,"eighty":-3.467127,"marketCap":550264684},{"date":"2024-01-05","current":-1.713833,"twenty":-21.128686,"median":-13.967112,"eighty":-3.374494,"marketCap":570457884},{"date":"2024-01-12","current":-1.622833,"twenty":-20.999951,"median":-13.847237,"eighty":-3.288105,"marketCap":540168085},{"date":"2024-01-19","current":-1.617777,"twenty":-20.926148,"median":-13.775851,"eighty":-3.237951,"marketCap":538485318},{"date":"2024-01-26","current":-1.617777,"twenty":-20.843295,"median":-13.725947,"eighty":-3.189059,"marketCap":538485318},{"date":"2024-02-02","current":-1.875611,"twenty":-20.757114,"median":-13.643018,"eighty":-3.045151,"marketCap":624306416},{"date":"2024-02-09","current":-2.209277,"twenty":-20.678726,"median":-13.581145,"eighty":-2.954746,"marketCap":735369012},{"date":"2024-02-16","current":-2.507555,"twenty":-20.569541,"median":-13.523798,"eighty":-2.866187,"marketCap":834652243},{"date":"2024-02-23","current":-2.204222,"twenty":-20.53631,"median":-13.479021,"eighty":-2.792973,"marketCap":733686246},{"date":"2024-03-01","current":-2.482277,"twenty":-20.368481,"median":-13.450518,"eighty":-2.74483,"marketCap":826238410},{"date":"2024-03-08","current":-2.815944,"twenty":-20.232312,"median":-13.366427,"eighty":-2.733115,"marketCap":937301007},{"date":"2024-03-15","current":-2.316309,"twenty":-20.232312,"median":-13.215177,"eighty":-2.663292,"marketCap":758046859},{"date":"2024-03-22","current":-2.263068,"twenty":-20.232312,"median":-13.137784,"eighty":-2.619459,"marketCap":740622924},{"date":"2024-03-28","current":-2.304402,"twenty":-20.232312,"median":-12.979561,"eighty":-2.590948,"marketCap":754150284},{"date":"2024-04-05","current":-2.092563,"twenty":-20.235598,"median":-12.656765,"eighty":-2.565844,"marketCap":684822567},{"date":"2024-04-12","current":-2.061562,"twenty":-20.235598,"median":-12.436968,"eighty":-2.524426,"marketCap":674677048},{"date":"2024-04-19","current":-1.78772,"twenty":-20.235598,"median":-11.170164,"eighty":-2.507555,"marketCap":585058292},{"date":"2024-04-26","current":-1.489357,"twenty":-20.232312,"median":-10.939939,"eighty":-2.476779,"marketCap":487414450},{"date":"2024-05-03","current":-1.549349,"twenty":-20.232312,"median":-10.763718,"eighty":-2.449125,"marketCap":507047607},{"date":"2024-05-10","current":-1.491965,"twenty":-20.232312,"median":-10.570442,"eighty":-2.423446,"marketCap":488268066},{"date":"2024-05-17","current":-2.150009,"twenty":-20.232312,"median":-10.267339,"eighty":-2.404926,"marketCap":628441086},{"date":"2024-05-24","current":-1.814293,"twenty":-20.232312,"median":-10.217798,"eighty":-2.379795,"marketCap":530312411},{"date":"2024-05-31","current":-1.75715,"twenty":-20.232312,"median":-9.802255,"eighty":-2.357966,"marketCap":513609658},{"date":"2024-06-07","current":-1.721436,"twenty":-20.232312,"median":-9.458326,"eighty":-2.340512,"marketCap":503170437},{"date":"2024-06-14","current":-1.814293,"twenty":-20.235598,"median":-9.321335,"eighty":-2.329295,"marketCap":530312411},{"date":"2024-06-21","current":-1.742864,"twenty":-20.238885,"median":-8.808228,"eighty":-2.309886,"marketCap":509433970},{"date":"2024-06-28","current":-1.742864,"twenty":-20.242458,"median":-8.742856,"eighty":-2.294956,"marketCap":509433970},{"date":"2024-07-05","current":-1.48572,"twenty":-20.242458,"median":-8.481366,"eighty":-2.266168,"marketCap":434271581},{"date":"2024-07-12","current":-1.914293,"twenty":-20.242458,"median":-8.062204,"eighty":-2.243046,"marketCap":559542229},{"date":"2024-07-15","current":-1.971437,"twenty":-20.242458,"median":-8.020916,"eighty":-2.232295,"marketCap":576244982},{"date":"2024-08-02","current":-1.957151,"twenty":-20.349588,"median":-7.694054,"eighty":-2.214333,"marketCap":572069294},{"date":"2024-08-09","current":-1.766151,"twenty":-20.242888,"median":-7.361135,"eighty":-2.204222,"marketCap":493503177},{"date":"2024-08-16","current":-1.721249,"twenty":-20.191056,"median":-7.164846,"eighty":-2.190823,"marketCap":480956486},{"date":"2024-08-23","current":-1.938276,"twenty":-20.093845,"median":-6.95807,"eighty":-2.175232,"marketCap":541598826},{"date":"2024-08-30","current":-1.990662,"twenty":-20.017285,"median":-6.784225,"eighty":-2.163853,"marketCap":556236632},{"date":"2024-09-06","current":-1.878406,"twenty":-19.907815,"median":-6.720841,"eighty":-2.145966,"marketCap":524869905},{"date":"2024-09-13","current":-1.990662,"twenty":-19.841932,"median":-6.638141,"eighty":-2.137278,"marketCap":556236632},{"date":"2024-09-20","current":-2.177754,"twenty":-19.740366,"median":-6.52603,"eighty":-2.12858,"marketCap":608514511},{"date":"2024-09-27","current":-2.035564,"twenty":-19.655531,"median":-6.451977,"eighty":-2.11323,"marketCap":568783323},{"date":"2024-10-04","current":-1.953243,"twenty":-19.537191,"median":-6.405838,"eighty":-2.102896,"marketCap":545781056},{"date":"2024-10-11","current":-1.960727,"twenty":-19.451161,"median":-6.340592,"eighty":-2.095433,"marketCap":547872171},{"date":"2024-10-18","current":-2.013113,"twenty":-19.182572,"median":-6.263289,"eighty":-2.085149,"marketCap":562509978},{"date":"2024-10-25","current":-1.900857,"twenty":-19.099967,"median":-6.094411,"eighty":-2.082942,"marketCap":531143250},{"date":"2024-10-31","current":-1.975694,"twenty":-18.987548,"median":-5.997212,"eighty":-2.068419,"marketCap":552054402},{"date":"2024-11-08","current":-2.345511,"twenty":-18.8198,"median":-5.784847,"eighty":-2.066176,"marketCap":667065736},{"date":"2024-11-15","current":-1.819833,"twenty":-18.730117,"median":-5.685597,"eighty":-2.062069,"marketCap":515793343},{"date":"2024-11-22","current":-1.560913,"twenty":-18.672674,"median":-5.55799,"eighty":-2.057716,"marketCap":442408112},{"date":"2024-11-29","current":-1.834628,"twenty":-18.617559,"median":-5.526672,"eighty":-2.050374,"marketCap":519986785},{"date":"2024-12-06","current":-1.583106,"twenty":-18.544789,"median":-5.472919,"eighty":-2.035564,"marketCap":448698274},{"date":"2024-12-13","current":-1.494334,"twenty":-18.484968,"median":-5.388824,"eighty":-2.012971,"marketCap":423537623},{"date":"2024-12-20","current":-1.361176,"twenty":-18.434448,"median":-5.342087,"eighty":-2.004132,"marketCap":385796647},{"date":"2024-12-27","current":-1.6053,"twenty":-18.274255,"median":-5.271168,"eighty":-1.99543,"marketCap":454988437},{"date":"2025-01-03","current":-1.627493,"twenty":-18.232743,"median":-5.246062,"eighty":-1.989226,"marketCap":461278600},{"date":"2025-01-10","current":-1.738458,"twenty":-18.134947,"median":-5.165179,"eighty":-1.981988,"marketCap":492729413},{"date":"2025-01-17","current":-1.361176,"twenty":-18.049948,"median":-5.108399,"eighty":-1.973991,"marketCap":385796647},{"date":"2025-01-24","current":-1.390766,"twenty":-17.95056,"median":-5.083674,"eighty":-1.968071,"marketCap":394183531},{"date":"2025-01-31","current":-1.420357,"twenty":-17.937793,"median":-5.049325,"eighty":-1.960727,"marketCap":402570414},{"date":"2025-02-07","current":-1.183631,"twenty":-17.868445,"median":-4.992941,"eighty":-1.952685,"marketCap":335475345},{"date":"2025-02-14","current":-1.043075,"twenty":-17.655471,"median":-4.937742,"eighty":-1.935282,"marketCap":295637648},{"date":"2025-02-21","current":-1.66818,"twenty":-17.555207,"median":-4.886637,"eighty":-1.928217,"marketCap":472810565},{"date":"2025-02-28","current":-1.44255,"twenty":-17.34147,"median":-4.837622,"eighty":-1.918389,"marketCap":408860577},{"date":"2025-03-07","current":-1.494334,"twenty":-17.020068,"median":-4.776822,"eighty":-1.896028,"marketCap":423537623},{"date":"2025-03-14","current":-1.594124,"twenty":-16.872428,"median":-4.732391,"eighty":-1.881608,"marketCap":410630354},{"date":"2025-03-21","current":-1.374826,"twenty":-16.872428,"median":-4.701784,"eighty":-1.868669,"marketCap":354141522},{"date":"2025-03-28","current":-1.315785,"twenty":-16.872428,"median":-4.660179,"eighty":-1.851045,"marketCap":338932991},{"date":"2025-04-04","current":-1.163963,"twenty":-16.872428,"median":-4.603301,"eighty":-1.838423,"marketCap":299825338},{"date":"2025-04-11","current":-1.155529,"twenty":-16.870721,"median":-4.547239,"eighty":-1.835284,"marketCap":297652691},{"date":"2025-04-17","current":-1.180832,"twenty":-16.643496,"median":-4.506056,"eighty":-1.832263,"marketCap":304170633},{"date":"2025-04-23","current":-1.341088,"twenty":-16.455771,"median":-4.465773,"eighty":-1.82327,"marketCap":345450933}],"updateTime":1745557811443}}}